Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD5 | P21918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11254068 | 0.89 | HRH1 (0.63) | HRH1HTR1BDRD2DRD1DRD4 | |
| SCHEMBL3066804 | 0.87 | HRH1 (0.56) | HRH1DRD2DRD1DRD4DRD5 | |
| SCHEMBL3058007 | 0.85 | DRD2 (0.55) | HRH1DRD2DRD1DRD4DRD5 | |
| SCHEMBL7999552 | 0.84 | PPARD (0.60) | — | |
| SCHEMBL11253910 | 0.84 | HRH1 (0.75) | HRH1DRD2DRD1DRD4DRD5 | |
| SCHEMBL8703033 | 0.84 | HRH1 (0.61) | HRH1HTR1BDRD2DRD1DRD4 | |
| SCHEMBL11259882 | 0.84 | HRH1 (0.57) | HRH1HTR1BDRD2DRD1DRD4 | |
| SCHEMBL8698766 | 0.83 | HRH1 (0.69) | HRH1HTR1BDRD2DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL11256997 | 0.83 | HRH1 (0.73) | HRH1DRD2DRD1DRD4DRD5 | |
| SCHEMBL11250748 | 0.83 | HRH1 (0.60) | HRH1HTR1BDRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HRH1 596/4885HTR1B 1551/4885DRD2 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.